PD-1/L1 inhibitors
4 abstracts
Abstract
Real-world first-line treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma in the United States.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, Astellas Pharma Inc., Astellas Pharma, Inc., Analysis Group, Inc., Pfizer Inc.,
Abstract
The activity and safety of icaritin for patients with unresectable HCC: A real world, retrospective study.Org: Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou, China, Tianjin First Center Hospital, Tianjin, China, First affiliated hospital of Xi'an Jiaotong University, Xian, China, Tianjin Third Center Hospital, Tianjin, China, Department of Interventional medicine,The Affiliated Hospital of Qingdao University, Qingdao, China,
Abstract
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.Org: University of California Irvine Medical Center, Santa Creu i Sant Pau Hospital, Seattle Cancer Care Alliance, IDIVAL, Barts Cancer Centre QMUL,
Abstract
A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors.Org: Second Affiliated Hospital of Soochow University, Institution of Radiotherapy & Oncology, Soochow University,